… These drugs work on a common pathway of blocking TNFα, a pro-inflammatory cytokine …
The incidence and prevalence of anaemia was approximately 19% and 28%, respectively, …

… Very early onset inflammatory bowel disease (VEO-IBD) is defined as IBD presenting before
… In addition, patients with VEO-IBD have a higher incidence of inflammatory bowel disease …

… diseases such as inflammatory bowel disease (IBD). IBD is a complicated inflammatory colitis
disorder; Crohn’s disease and … the development of new therapeutic opportunities for IBD. …

… therapies targeting several immune pathways have been developed for the treatment of
patients with inflammatory bowel disease … treatment for moderate to severe Crohn’s disease and …

… an inflammatory biomarker [256], are reduced in patients with inflammatory bowel diseases,
… levels are increased in patients with inflammatory bowel disease when compared to control …

… that trigger disease activity in chronic inflammatory bowel disease (IBD). Disruption of the
epithelial barrier, in the form of increased intestinal permeability, is a feature of IBD and other …

… intestinal homeostasis and inflammatory bowel disease. The cytosolic domain of the
transmembrane receptors for these factors include tyrosine residues (Y) that act as docking sites for …

… Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory
bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize …

… Inflammatory bowel disease (IBD) is a chronic systemic inflammatory condition. Previously,
the focus has been on extraintestinal manifestations of IBD, including arthritis, psoriasis, and …

… , and many other diseases. Over the past few decades, countless studies focusing on the
investigation of noninvasive diagnosis, pathogenesis, and therapeutics have revealed different …